Ann: Appendix 4C - quarterly, page-20

MSB have TWO options for getting product into the marketplace:

1) The first one, is a more traditional approach, which will, as you progress through late stage Ph2 and then into larger Ph3 trials, see a material increase in cash burn, hence the necessary strength in MSB's balance sheet - as has often been commented on, both by the directors and on these very boards.

2) The second approach, is somewhat unorthodox and to be honest, I can't really see the MSB Board embracing it. i) they build a huge bonfire on a beach and ii) the directors dance around it and united in voice, sing an ancient chant to the "magical drug development fairy" and after she sprinkles her magical "drug development dust", everyone wakes up the next morning, bank balance not touched and with multiple products now in major health markets, ranking in billion$ in sales a year - as I said, it's unorthodox - but wow, if they can pull it off!